Biogen Reaffirms FY22 Outlook; Q1 Adj. EPS Misses Estimates

While reporting financial results for the first quarter on Tuesday, Biogen Inc. (BIIB) reaffirmed its adjusted earnings and revenue guidance for the full-year 2022.

For fiscal 2022, the company continues to project adjusted earnings in the range of $14.25 to $16.00 per share on revenues between $9.70 billion and $10.0 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $15.44 per share on revenues of $9.87 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company reported net income attributable to the company of $303.8 million or $2.06 per share, down from $410.2 million or $2.69 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter were $3.62 per share, compared to $5.34 per share in the year-ago quarter.

Total revenue for the quarter declined 6 percent to $2.53 billion from $2.69 billion in the same quarter last year. Revenues were down 5 percent in constant currency.

The Street expected the company to report earnings of $4.38 per share on revenues of $2.50 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT